Contrarian Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Contrarian Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: pcyhuang	9/22/2006 10:19:28 PM
	Read Replies (6) of 4080

BSX -- Contrarian Investing Boston Scientific Corporation engages in the development, manufacture, and marketing of medical devices that are used in interventional medical specialties in Europe, and Japan. Forward P/E (fye 31-Dec-07): 15.15 PEG Ratio (5 yr expected): 1.53 Price/Sales (ttm): 3.55 Price/Book (mrq): 1.62 EBITDA (ttm)/Revenue (ttm): 2.74 Qtrly Revenue Growth (yoy): 30.50% Qtrly Earnings Growth (yoy): N/A Book Value Per Share (mrq): 10.12 Operating Cash Flow (ttm): 1.22B Levered Free Cash Flow (ttm): 7.75B 52-Week High (02-Dec-05): 27.82 52-Week Low (22-Sep-06): 14.43 Insiders' net buying $22,364,529 worth of stock since March 2005. secform4.com Institutional Sponsorship: 10 mutual funds hold the stock respectively as one of its top 10 holdings Capitulated volume: On Sept. 22, BSX ranked #1 in terms of downside capitulated volume, a total of 75,345,600 shares changed hand. 15 minute chart: stockcharts.com Note the amount of net buying since 3:p.m. Conclusion: Value + Insiders' buying & good institutional sponsorship + capitulated volume = Timely contrarian investing. pcyhuang

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next